{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:41:26Z","timestamp":1761986486337},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clinthera.2015.03.027","type":"journal-article","created":{"date-parts":[[2015,4,26]],"date-time":"2015-04-26T01:09:48Z","timestamp":1430010588000},"page":"1280-1291","source":"Crossref","is-referenced-by-count":17,"title":["Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors"],"prefix":"10.1016","volume":"37","author":[{"given":"Christine Y.","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Lakoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa G.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma K.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyse O.","family":"Kharbanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Lieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Soumerai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Chen Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.03.027_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11589350-000000000-00000","article-title":"Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?","volume":"34","author":"Gibbons","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2015.03.027_bib2","article-title":"FDA Panel Supports Retaining Chantix Boxed Warning for Now","author":"Mechcatie","year":"2014","journal-title":"Chest Physician"},{"key":"10.1016\/j.clinthera.2015.03.027_bib3","unstructured":"FDA. Early Communication About an Ongoing Safety Review of Montelukast (Singulair). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm070618.htm. Accessed April 15, 2015."},{"key":"10.1016\/j.clinthera.2015.03.027_bib4","unstructured":"FDA. Updated Information on Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm165489.htm. Accessed April 15, 2015."},{"key":"10.1016\/j.clinthera.2015.03.027_bib5","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1164\/rccm.201306-1017OC","article-title":"Statin exposure is associated with decreased asthma-related emergency department visits and oral corticosteroid use","volume":"188","author":"Tse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2015.03.027_bib6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/aje\/kwt323","article-title":"A comparison of confounding adjustment methods for assessment of asthma controller medication effectiveness","volume":"179","author":"Li","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2015.03.027_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamapediatrics.2014.79","article-title":"Financial barriers to care among low-income children with asthma: health care reform implications","volume":"168","author":"Fung","year":"2014","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.clinthera.2015.03.027_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2015.03.027_bib9","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/archinternmed.2009.39","article-title":"Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees","volume":"169","author":"Adams","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2015.03.027_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/MLR.0b013e3181bd4c10","article-title":"Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness","volume":"48","author":"Lu","year":"2010","journal-title":"Med Care"},{"key":"10.1016\/j.clinthera.2015.03.027_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clinthera.2011.01.012","article-title":"Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study","volume":"33","author":"Lu","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2015.03.027_bib12","doi-asserted-by":"crossref","first-page":"g3596","DOI":"10.1136\/bmj.g3596","article-title":"Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study","volume":"348","author":"Lu","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2015.03.027_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ambp.2007.10.007","article-title":"Racial\/ethnic variation in parent perceptions of asthma","volume":"8","author":"Wu","year":"2008","journal-title":"Ambul Pediatr"},{"key":"10.1016\/j.clinthera.2015.03.027_bib14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaip.2014.05.009","article-title":"Use of leukotriene receptor antagonists are associated with similar risk of asthma exacerbations as inhaled corticosteroids (In press)","volume":"2","author":"Wu","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clinthera.2015.03.027_bib15","unstructured":"Butler M, Zhou E, Zhang F, et al. Report of the Impact of 2010 FDA Regulatory Actions on LABA Medication Use. http:\/\/www.mini-sentinel.org\/work_products\/Assessments\/Mini-Sentinel_Impact-2010-FDA-Regulatory-Actions-LABA-Medication-Use.pdf. Accessed April 15, 2015."},{"key":"10.1016\/j.clinthera.2015.03.027_bib16","first-page":"SS","article-title":"Suicidal thoughts and behaviors among adults aged \u226518 years-United States, 2008-2009","volume":"60","author":"Crosby","year":"2011","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.clinthera.2015.03.027_bib17","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJMsa053737","article-title":"Behavioral health insurance parity for federal employees","volume":"354","author":"Goldman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.03.027_bib18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/pds.2037","article-title":"Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded","volume":"19","author":"Patrick","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2015.03.027_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/pds.3551","article-title":"How complete are E-codes in commercial plan claims databases?","volume":"23","author":"Lu","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2015.03.027_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jclinepi.2008.08.007","article-title":"Methods for estimating confidence intervals in interrupted time series analyses of health interventions","volume":"62","author":"Zhang","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2015.03.027_bib21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jaci.2012.04.035","article-title":"Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study","volume":"130","author":"Schumock","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2015.03.027_bib22","article-title":"Adverse effects of montelukast examined by FDA's Pediatric Advisory Committee","author":"Foxhall","year":"2014","journal-title":"Contemp Pediatr"},{"key":"10.1016\/j.clinthera.2015.03.027_bib23","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2165\/11318960-000000000-00000","article-title":"Messages about black-box warnings: a comparative analysis of reports from the FDA and lay media in the US","volume":"32","author":"Yong","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2015.03.027_bib24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MLR.0b013e31825852f0","article-title":"Communicating the risks of medicines: time to move forward","volume":"50","author":"Dal Pan","year":"2012","journal-title":"Med Care"},{"key":"10.1016\/j.clinthera.2015.03.027_bib25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/MLR.0b013e318245a160","article-title":"Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review","volume":"50","author":"Dusetzina","year":"2012","journal-title":"Med Care"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815001873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815001873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T01:29:01Z","timestamp":1537666141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815001873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0149291815001873"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.03.027","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}